Amylin Pharmaceuticals (AMLN)
News
| May 25 | Looking very sharp $AMLN http://chart.ly/9kpt2a5 by TradetheLeaders |
| May 25 | $AMLN low 30's easy on tues. Followed by buyout in mid to upper 30's by QR_Winner |
| May 25 | $AMLN halted? by QR_Winner |
| May 25 | Health Care Sector Wrap Fox Business |
| May 25 | Sara Lee, Amylin Pharmaceuticals Included in Stocks Up on High Volume Friday Fox Business |
| May 25 | RT @markflowchatter Great alert by @TradeHawk on $AMLN as usual,recall that alot of the firms think a deal gets done at $30 - $37 by epime7heus |
| May 25 | RT @epime7heus everyone picking up some $AMLN in case of buyout just before or after holiday weekend <----- 3:30 pm yesterday by epime7heus |
| May 25 | $ROSG $AMLN - $ROSG starting huge EOD RUN! by slimtrader |
| May 25 | Amylin Shares Jump as Sanofi, Merck Sumbit Bids Benzinga |
| May 25 | RT @tiernster $AMLN news says they received bids of at least $25? better b more then that - this is the 3rd time buyout talks increased pps by jackofalltrade |
| May 25 | Amylin (AMLN) Shares Jump as Bids Due Today, Sanofi (SNY), Merck (MRK) Said to Make F... |
| May 21 | The Definitive Biotech ETF Guide (IBB, XBI, FBT) Benzinga |
Profile
Exchange: NASDAQGS Sector: Healthcare Industry: Biotechnology
Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces two drugs, Symlin and Byetta . Amylin also is working on producing a drug based on Leptin. The company markets its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers, and other third-party payers primarily in the United States. It has collaboration agreements with Eli Lilly and Company; Alkermes, Inc.; Takeda Pharmaceutical Company Limited; Biocon, Ltd.; and Juvenile Diabetes Research Foundation International Inc. The company was founded in 1987 and is based in San Diego, California.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Amylin Pharmaceuticals is up 107.9% over the last year vs S&P 500 Total Return up 1.62%, Human Genome Sciences down 49.50%, and Bristol-Myers Squibb Company up 21.16%.
- AMLN Total Returns
- ^SPXTR Total Returns
- HGSI Total Returns
- BMY Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these AMLN related companies
Pro Strategies Featuring AMLN
Did Amylin Pharmaceuticals make it into our Pro Portfolio Strategies?
AMLN Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other AMLN Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AMLN | 27.96 | +2.16 | +8.37% | 4.496B |
| AMKR | 4.65 | +0.07 | +1.53% | 782.83M |
| AMJ | 37.36 | +0.23 | +0.62% | |
| AMIC | 4.35 | -0.34 | -7.25% | 35.97M |
| AMGN | 69.05 | -0.05 | -0.07% | 54.16B |
| AMG | 103.47 | -0.33 | -0.32% | 5.356B |
| AME | 49.22 | -0.44 | -0.89% | 7.911B |
| AMD | 6.22 | +0.20 | +3.32% | 4.350B |
| AIQ | 1.05 | -0.02 | -1.87% | 55.99M |
| AINV | 7.46 | -0.03 | -0.40% | 1.470B |
